ZVRA
Zevra Therapeutics, Inc.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Zvera investors saw shares fall roughly 24% after European regulators issued a negative CHMP opinion on arimoclomol. The investigation focuses on whether investors who suffered losses may have potenti
